Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PREVENTION OF THROMBOSIS AND RETHROMBOSIS AND ENHANCEMENT OF THE THROMBOLYTIC ACTIONS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN THE CANINE HEART BY DMP728, A GLYCOPROTEIN IIB IIIA ANTAGONIST/
Autore:
LUCCHESSI BR; ROTE WE; DRISCOLL EM; MU DX;
Indirizzi:
UNIV MICHIGAN,SCH MED,DEPT PHARMACOL ANN ARBOR MI 48109
Titolo Testata:
British Journal of Pharmacology
fascicolo: 4, volume: 113, anno: 1994,
pagine: 1333 - 1343
SICI:
0007-1188(1994)113:4<1333:POTARA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY REPERFUSION; IIB-IIIA RECEPTOR; PLATELET ACTIVATION; ANTITHROMBOTIC AGENTS; VASCULAR OCCLUSION; UNSTABLE ANGINA; ANTIPLATELET; IIB/IIIA; INHIBITION; ANTIBODY;
Keywords:
FIBRINOGEN RECEPTOR; ANTIPLATETLET AGENT; THROMBOLYSIS; INTEGRIN RECEPTOR; DMP728;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
57
Recensione:
Indirizzi per estratti:
Citazione:
B.R. Lucchessi et al., "PREVENTION OF THROMBOSIS AND RETHROMBOSIS AND ENHANCEMENT OF THE THROMBOLYTIC ACTIONS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN THE CANINE HEART BY DMP728, A GLYCOPROTEIN IIB IIIA ANTAGONIST/", British Journal of Pharmacology, 113(4), 1994, pp. 1333-1343

Abstract

1 We studied DMP728, a non-peptide glycoprotein (GP) IIb/IIIa receptor antagonist, for prevention of coronary artery thrombosis or rethrombosis in a chronic canine model subjected to arterial injury. 2 In protocol I, DMP728 (1.0 mg kg(-1), i.v., n = 8) or saline (n = 8) was administered and a 150 mu A anodal current was applied to the intimal surface of the left circumflex coronary artery (LCX). Dogs were monitored for 6 h and again on each of 5 subsequent days. 3 Ex vivo platelet aggregation was inhibited but returned to baseline 1 day after drug administration. Thrombus weight was reduced (saline, 20.7 +/- 5.0 mg; DMP728 1.7 +/- 0.4 mg; P<0.05), as was infarct size [saline, 27.5 +/- 4.3; DMP728, 1.6 +/- 0.7 (per cent left ventricle); P<0.05]. All control animals died by day 3, while all but one of the treated dogs survived the entire protocol (P<0.05). 4 In protocol II, an LCX thrombus was induced and thrombolytic therapy was initiated 30 min later. DMP728 (1.0 mg kg(-1), i.v., n = 8) or saline (n = 8) was administered 5 min after recombinant tissue-type plasminogen activator infusion had begun. The incidence of reocclusion was reduced by DMP728 (saline, 4/8; DMP728, 1/8). One day after thrombolysis, 7/8 DMP728-treated animals were alivecompared with 1/8 in the control group (P = 0.01). 5 DMP728 inhibitedex vivo platelet aggregation, prevented primary and secondary occlusive thrombus formation, reduced thrombus weight and infarct size and increased survival in a chronic canine model of coronary artery thrombusformation. DMP728 is an effective anti-platelet intervention when used as the singular adjunctive agent in association with thrombolytic therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 03:44:36